Author

Graham Beaton

ORCID 0000-0002-7705-1952Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:zebrafish· 1

Frequent Co-Authors

Ambrosio Lopez· 1 shared Ann C.M. Tuma· 1 shared Ashwani KumariD· 1 shared Bennett Stork· 1 shared Bryan W. DayiD· 1 shared Daniel J. GaramaiD· 1 shared Daniel J. GoughiD· 1 shared Fábio C. TucciiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ambrosio Lopez

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma

Sameer A. Greenall, Shengnan C Chen, Gordon Alton, Graham Beaton, Reghan Boelter, Teresa Venezia Bowman, Ivan Babić, Zara C. Bruce, Daniel J. Garama, Rajesh Mukthavaram, Fábio C. Tucci, Ravula Satheesh Babu, Ambrosio Lopez, Susan K. Knowles, Gregory Stein, , Rohan G. T. Lowe

This study shows that CT-179, an OLIG2 inhibitor, reduces glioblastoma growth and enhances chemoradiotherapy efficacy in preclinical models.

bioRxiv · Oct 20, 2026 · PreprintCancer Biology